Evaluation of the duration of dual-antiplatelet therapy after percutaneous coronary intervention: a retrospective audit on the compliance with guidelines or cardiologist recommendation

Introduction Clinical guidelines define 12 months or less of dual antiplatelet therapy (DAPT) as standard therapy post-percutaneous coronary intervention (PCI). The aim of this study was to determine the proportion of patients taking DAPT post-PCI for the appropriate duration recommended by guidelines or the treating cardiologist at a large tertiary hospital in Brisbane. Methods A total of 105 patients, who were first admitted to Princess Alexandra Hospital (PAH) for PCI and were subsequently readmitted at least 12 months later, were audited. The appropriateness of continuation or cessation of DAPT was determined by comparing actual duration with the duration planned by the cardiologist and the duration recommended by clinical guidelines. Results Sixty-six percent (n = 70) of patients were found to be still taking DAPT on readmission. DAPT duration for 32% (n = 34) patients was compliant with the recommendations of guidelines or treating cardiologist, with 10% (n = 11) and 57% (n = 60) being shorter and longer than recommendations of guidelines or treating cardiologist respectively. Conclusion Unwarranted extended use of DAPT is highly prevalent at the Princess Alexandra Hospital, and places patients at risk of bleeding complications.